fbpx

Day

October 1, 2014
Ness Ziona, Israel - September 29, 2014 - Atox Bio, a clinical stage company developing novel immunemodulators for severe infections, today announced that the Biomedical Advanced Research and Development Authority (BARDA) has awarded Atox Bio with a contract valued up to $24 million and 4.5 years for the development of AB103 to treat Necrotizing Soft...

News

Seven research institutions receive DKK 20 million for coronavirus research
1. April 2020
How we handle changes to research projects in light of the coronavirus pandemic
31. March 2020
Lundbeck Foundation gives its first coronavirus grant to trial with a known drug
26. March 2020

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge